Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00795093 · ClinicalTrials.gov registry record
Partial Response to Proton Pump Inhibitors (PPI) Treatment: The Cost to Society and the Burden to the Patient - a Study in the US
A clinical trial, sponsored by AstraZeneca.
- Completed
- Registry status
- 552
- Enrollment target
NCT00795093: Completed study, sponsored by AstraZeneca.
NCT00795093 is a clinical trial that has completed, run by AstraZeneca. The registered enrollment target is 552 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00795093 has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- 552 participants
- Enrollment target
Study Summary
The purpose of this study is to describe common treatment pathways, to collect health care utilization data and to assess symptom load as well as impact of symptoms on daily life in GERD patients who are partial-responders to PPI treatment.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 552 participants |
| Start Date | 2008-11 |
| Est. Completion | 2010-01 |
What the finished NCT00795093 record still lists
NCT00795093 is an observational study that tracks outcomes without assigning an intervention. The registered 552 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT00795093 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00795093 about?
NCT00795093 is a clinical study titled "Partial Response to Proton Pump Inhibitors (PPI) Treatment: The Cost to Society and the Burden to the Patient - a Study in the US". The purpose of this study is to describe common treatment pathways, to collect health care utilization data and to assess symptom load as well as impact of symptoms on daily life in GERD patients who are partial-responders to PPI treatment.
What is the current status of trial NCT00795093?
This trial is currently completed. The enrollment target is 552 participants. The study started on 2008-11. Estimated completion is 2010-01.
Who is sponsoring clinical trial NCT00795093?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06217809 · 552 participants · NA
EmpowHer is Prevention Curriculum for Youth Ages 10-15 Years.
- NCT07146022 · 552 participants · Phase 3
Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA)
- NCT05786924 · 554 participants · Phase 1
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- NCT01852448 · 550 participants
Genetics of Insulin and Incretins in Cystic Fibrosis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia